Skip to main content

Table 8 Patients TMB10 + and b) TMMQ1 + according to mutational status

From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

a)

 

TMB10 -

TMB10 +

Total no. patients

DWT

87

43

130

RB1 only

7

3

10

TP53 only

55

46

101

RB1 & TP53

14

19

33

Chi2, p = 0.037

   

b)

   
 

TMMQ1 +

TMMQ1 -

Total no. patients

DWT

29

101

130

RB1 only

4

6

10

TP53 only

27

74

101

RB1 & TP53

15

18

33

Chi2, p = 0.048